| Dr Daniel Roll, PHARM D | |
|
8b Woodmont Dr, Point Pleasant, WV 25550-2020 | |
| (304) 593-9988 | |
| Not Available |
| Full Name | Dr Daniel Roll |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 8b Woodmont Dr, Point Pleasant, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922375831 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP0007805 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Roll, PHARM D 8b Woodmont Dr, Point Pleasant, WV 25550-2020 Ph: () - | Dr Daniel Roll, PHARM D 8b Woodmont Dr, Point Pleasant, WV 25550-2020 Ph: (304) 593-9988 |
News Archive
Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco.
"Cigarette smoking is an important cause of cardiovascular disease, and smoking cessation reduces the risk. However, weight gain after smoking cessation may increase the risk of diabetes and weaken the benefit of quitting," write Juhua Luo, Ph.D., of the Indiana University School of Public Health, Bloomington, Ind., and colleagues.
A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system.
Zika virus. Ebola virus. Influenza. SARS and MERS corona viruses. Existing and emerging viral diseases are an increasing problem, particularly in developing countries. The World Health Organization has called for better control of viral diseases, but developing drugs for this purpose can be challenging.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
› Verified 5 days ago
John Michael Beaver Ii, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2520 Valley Dr, Point Pleasant, WV 25550 Phone: 304-674-2412 Fax: 304-675-7150 | |
Dr. Dakota Toth, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2501 Jackson Ave, Point Pleasant, WV 25550 Phone: 304-675-2303 | |
Jamie Bennett, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2501 Jackson Ave, Point Pleasant, WV 25550 Phone: 304-675-2303 | |
Dr. Michael Durst, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4016 Ohio River Rd, Point Pleasant, WV 25550 Phone: 304-675-1612 | |
Dr. Christopher Childress, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2501 Jackson Ave, Point Pleasant, WV 25550 Phone: 304-675-2303 | |
Rumsey Oates, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2501 Jackson Ave, Point Pleasant, WV 25550 Phone: 304-675-2303 Fax: 304-675-7762 | |
Gary Hatfield Ii, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4016 Ohio River Rd, Point Pleasant, WV 25550 Phone: 304-675-1612 |